PIRS Pieris Pharmaceuticals Inc.

5.59
0  0%
Previous Close 5.59
Open 5.6
Price To Book 14.33
Market Cap 276,105,227
Shares 49,392,706
Volume 85,791
Short Ratio
Av. Daily Volume 595,613

NewsSee all news

  1. Pieris Pharmaceuticals Announces Changes to Senior Management Team

    BOSTON, MA / ACCESSWIRE / September 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for

  2. Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

    BOSTON, MA / ACCESSWIRE / August 29, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data presented at EHA June 16, 2019.
PRS-080
Anemia of chronic disease
Phase 1 presentation at European Respiratory Society International Congress, October 1, 2019.
PRS-060
Asthma
Phase 1 data due later in 2019.
PRS-343
HER2-positive solid tumors
Phase 1 data due later in 2019.
PRS-343 and atezolizumab (Tecentriq)
HER2-positive solid tumors

Latest News

  1. Pieris Pharmaceuticals Announces Changes to Senior Management Team

    BOSTON, MA / ACCESSWIRE / September 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for

  2. Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

    BOSTON, MA / ACCESSWIRE / August 29, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for